

----- Forwarded message -----

From: [REDACTED]
Date: Mon, Mar 16, 2026 at 11:23 PM
Subject: [WARNING: MESSAGE ENCRYPTED]USFDA - FMD 145 EIR - Anuh
Pharma Limited - 3001174909
To: [REDACTED]
[REDACTED]

03/16/2026

Mr. Gulshan Sharma, General Manager/Site Head
Anuh Pharma Limited
E-17/3, 17/4 & E-18, M.I.D.C., Tarapur, Boisar Palghar
District, Maharashtra

Dear Mr. Gulshan Sharma, General Manager/Site Head:

The U.S. Food and Drug Administration (FDA) conducted an inspection at Anuh Pharma Limited, FEI 3001174909, located at E-17/3, 17/4 & E-18, M.I.D.C., Tarapur, Boisar, Palghar District, Maharashtra, from 02/02/2026 to 02/06/2026. FDA has determined that the inspection classification of this facility is "no action indicated" ("NAI"). Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of NAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by the appropriate CDER or CVM review office. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "'closed'" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact Atul J. Agrawal or our inbox via email at [REDACTED] or [REDACTED]

[REDACTED], respectively.

Sincerely,

Atul J. Agrawal
Division Director
Division of Human and Animal Drug Foreign Inspectorate
(DHADFI)



U.S. FOOD & DRUG
ADMINISTRATION

UNCONTROLLED COPY